Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

ClinicalTrials.gov ID: NCT02405442

Public ClinicalTrials.gov record NCT02405442. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will primarily evaluate the safety and efficacy of andecaliximab in adults with active Crohn's disease. The study will consist of a Double-Blind Phase of 8 weeks followed by an Open-Label Extension. Participants who complete the Double-Blind Phase will be eligible to enroll in the optional Open-Label Extension for an additional 44 weeks. Participants who complete Week 52 assessments will be eligible to enter the Extended Treatment Phase to continue treatment with andecaliximab for an additional 156 weeks.

Study identification

NCT ID
NCT02405442
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Gilead Sciences
Industry
Enrollment
187 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2015
Primary completion
Nov 29, 2016
Completion
Dec 21, 2016
Last update posted
Apr 22, 2019

2015 – 2016

United States locations

U.S. sites
33
U.S. states
22
U.S. cities
33
Facility City State ZIP Site status
Digestive Health Specialists of The Southeast Dothan Alabama
Mayo Clinic Scottsdale Arizona
Cedars Sinai Medical Center Los Angeles California
South Denver Gastroenterology Lone Tree Colorado
University of Miami Miami Florida
Gastroenterology Group Of Naples Naples Florida
Gastroenterology Associates Of Central Georgia, LLC Macon Georgia
Medical Diagnostic Center (MDC)-Indiana University (IU) Health University Hospital Indianapolis Indiana
Iowa Digestive Disease Center Clive Iowa
Cotton-O'Neil Clinical Research Center, Digestive Health Topeka Kansas
Delta Research Partners Monroe Louisiana
Louisiana Research Center Shreveport Louisiana
University of Michigan Ann Arbor Michigan
Clinical Research Institute of Michigan, LLC Chesterfield Michigan
Mayo Clinic Rochester Rochester Minnesota
Washington University School of Medicine St Louis Missouri
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire
AGA Clinical Research Associates, LLC Egg Harbor New Jersey
Columbia University Medical Center/ New York Presbyterian New York New York
Premier Medical Group Of The Hudson Valley Poughkeepsie New York
Mayo Clinic Rochester Rochester New York
Asheville Gastroenterology Associates Asheville North Carolina
Consultants For Clinical Research Cincinnati Ohio
Great Lakes Gastroenterology Mentor Ohio
Gastro One Germantown Tennessee
Vanderbilt University Medical Center Nashville Tennessee
Texas Clinical Research Institute Arlington Texas
Ertan Digestive Disease Center of Excellence, UTH/MH-TMC Houston Texas
Gastroenterology Research of San Antonio San Antonio Texas
Gastroenterology Associates Of Tidewater Chesapeake Virginia
Digestive and Liver Disease Specialists Norfolk Virginia
Mcguire Dvamc Richmond Virginia
University of Washington Medical Center Seattle Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02405442, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 22, 2019 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02405442 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →